Abstract 76P
Background
Circulating tumor DNA (ctDNA) represents a promising prognostic biomarker for predicting relapse and overall survival in patients with metastatic pancreatic cancer (PC). To test the clinical applicable prognostic value of ctDNA dynamics during treatment, we aimed to detect response to treatment ahead of radiological restaging.
Methods
ctDNA detection using liquid biopsy (ddPCR utilizing KRAS G12/13 (and, if negative, Q61) commercial test kits) was prospectively performed on 70 patients with stage IV PC (i) prior to initiation of systemic chemotherapy and (ii) serially every two weeks until restaging.
Results
Detection rate at baseline was 64.3% (45/70). Reduction of ctDNA levels below 57.9% of its baseline value at week 2 after treatment initiation was significantly predictive for response to treatment (AUC=0.918, sensitivity 91.67%, specificity 100%) and was associated with prolonged overall survival (OS) (5.7 vs. 11.4 months, p=0.006) and progression free survival (PFS) (2.5 vs. 7.7 months, p<0.000) regardless of treatment line. Pretherapeutic ctDNA detection was independently associated with worse OS in patients receiving first line regimen (7 vs. 11.3 months, p=0.046) and regardless of treatment line (11.4 vs. 15.9 months, p=0.045) and associated with worse PFS (3.4 vs. 10.8 months, p=0.018).
Conclusions
The dynamic change of ctDNA during systemic treatment allows the prediction of treatment response and is associated with OS and PFS. Progressive disease was correctly predicted in 100% of patients with preemptive detectable ctDNA after 2 weeks (ctDNA) compared to 12 weeks with current gold standard (CT), enabling change of treatment >80% earlier hereafter.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
H. Rumpold.
Funding
Vinzenzgruppe Austria and Krebshilfe Oberösterreich.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2P - SOT102, a novel CLDN18.2-targeting antibody-drug conjugate for gastric and pancreatic cancer with a wide range of the tumor target expression
Presenter: Radek Spisek
Session: Cocktail & Poster Display session
Resources:
Abstract
3P - Correlation between antibody-drug conjugate (ADC) targetable antigen expression and occurrence of interstitial lung disease (ILD)
Presenter: Solange Peters
Session: Cocktail & Poster Display session
Resources:
Abstract
4P - Optimizing utilization of antibody-drug conjugates in NSCLC by identification of subsets using RNA sequencing
Presenter: Edwin Lin
Session: Cocktail & Poster Display session
Resources:
Abstract
5P - Tisotumab vedotin (TV) dose schedule optimization in non-cervical populations
Presenter: Jenna Voellinger
Session: Cocktail & Poster Display session
Resources:
Abstract
6P - RC48-ADC for metastatic salivary duct carcinoma with HER2 expression: A single-center retrospective study
Presenter: jun Cao
Session: Cocktail & Poster Display session
Resources:
Abstract
7P - Global ring study determining reproducibility & comparability of CLDN18 testing assays in gastric cancer
Presenter: Bharat Jasani
Session: Cocktail & Poster Display session
Resources:
Abstract
8P - Targeting antiapoptotic Bcl-2 proteins with highly specific BH3 mimetics in solid tumors
Presenter: Benjamin Sobol
Session: Cocktail & Poster Display session
Resources:
Abstract
9P - An in vivo model for therapeutic antibody efficacy evaluation: The chicken embryo’s CAM-based assay
Presenter: Yan Wang
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - Successful transfer and prolonged persistence of engineered lymphocytes with T-cell receptor targeting NY-ESO-1
Presenter: Johnathan Arnon
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - CRISPR/Cas9-induced knock-out of DGKαζ in TAG-72 CAR-T cells improves function and persistence in ovarian cancer
Presenter: Vera Evtimov
Session: Cocktail & Poster Display session
Resources:
Abstract